PT  - JOURNAL ARTICLE
AU  - Karanja, Henry K.
AU  - Orindi, Benedict
AU  - Gitonga, John N.
AU  - Mugo, Daisy
AU  - Mwai, Kennedy
AU  - Nyamwaya, Doris K.
AU  - Omuoyo, Donwilliams
AU  - Kitsao, Barnes S.
AU  - Musyoki, Jennifer N.
AU  - Wambua, Julianna
AU  - Otieno, Edward
AU  - Ochola-Oyier, Lynette Isabella
AU  - Bejon, Philip
AU  - Warimwe, George M.
TI  - Temporal trends of dengue seroprevalence among children in coastal Kenya, 1998–2018: a longitudinal cohort study
AID  - 10.1101/2023.08.13.23294039
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.08.13.23294039
4099  - http://medrxiv.org/content/early/2023/08/16/2023.08.13.23294039.short
4100  - http://medrxiv.org/content/early/2023/08/16/2023.08.13.23294039.full
AB  - Serosurveys suggest widespread dengue virus (DENV) transmission in Africa but there is limited information on the temporal patterns of exposure. Here, we estimated the prevalence and incidence of DENV infections in coastal Kenya over a 20-year period (1998–2018). Sera (n=8038) obtained annually from a longitudinal cohort of 1847 children aged 15 years and below were screened for anti-DENV IgG antibodies. Anti-DENV IgG seroprevalence increased with age and peaked during outbreak years. Among 1354 children who were seronegative at recruitment, we observed an overall incidence (seroconversion) rate of 129.5 (95% CI 118.7–141.4) DENV infections per 1000 person-years. The highest incidence was observed in 2013 at 520 infections per 1000 person-years (95% CI 443.6–610.2) coinciding with a large DENV outbreak in coastal Kenya. Our data suggest long-term DENV exposure among children in coastal Kenya highlighting an urgent need for clinical surveillance to determine the associated health burden in this setting.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by Wellcome Trust grant (grant number 203077_Z_16_Z to PB) and an Oak Foundation fellowship to GMW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Scientific and Ethics Review Unit of the Kenya Medical Research Institute gave ethical approval for this work(KEMRI SERU # 3296, #1131)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript